A Controlled Trial of Ondansetron, a 5-HT3 Antagonist, in Benzodiazepine Discontinuation
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Serotonin is implicated in the etiology of anxiety disorders and in the anxiolytic actions of benzodiazepines. Preclinical studies with 5-HT3 receptor antagonists, including ondansetron, show they have anxiolytic properties and that ondansetron suppresses withdrawal anxiety after abrupt discontinuation of chronic benzodiazepine treatment. We evaluated the efficacy of ondansetron as an adjunctive medication in the discontinuation of benzodiazepines in long-term users. One hundred eight patients who had used alprazolam or lorazepam regularly for > 3 months entered, and 97 completed a randomized double-blind discontinuation treatment program during which they received either ondansetron 2 mg twice daily or placebo and flexibly tapered their benzodiazepine over a 6-week period. There were no significant differences between the patients who had entered and completed treatment. Three weeks postmedication, 63% of the patients discontinued use of benzodiazepine. The percentage of reduction of benzodiazepine daily dosage at all time points in the treatment trial was similar for the ondansetron and placebo groups. Ondansetron had no significant effects on severity of withdrawal symptoms or levels of anxiety. High placebo response may have prevented detection of an ondansetron effect. At 1 year follow-up, 68% of patients reported that they stopped using benzodiazepine. Patient characteristics were more important than ondansetron in tapered benzodiazepine discontinuation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Benzodiazepine withdrawal symptoms and propranolol
TYRER, P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92861-0 · Cited by 297
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.10.1485 · Cited by 263
Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper
Schweizer, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220024003 · Cited by 191
Does Cognitive Behavior Therapy Assist Slow-Taper Alprazolam Discontinuation in Panic Disorder?
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.876 · Cited by 153
The Two-Period Crossover Design in Medical Research
Woods, J. R., Williams, J. G., & Tavel, M. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-7-560 · Cited by 139
A Comparison of Buspirone and Placebo in Relieving Benzodiazepine Withdrawal Symptoms
LADER, M., & OLAJIDE, D. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198702000-00003 · Cited by 79
Cantopher, T., Olivieri, S., Cleave, N., & Edwards, J. G. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.156.3.406 · Cited by 67
Cited by
A review of 25 years of the social interaction test
File, S. E., & Seth, P. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01273-1 · Cited by 742
Withdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318
“[43-50] Many ed as a ‘pure’ antagonist, subsequent work in both other studies were excluded for a variety of reasons, animals and humans has suggested that flumazenil is including inappropriate outcome measures, setting a mixed agonist/antagonist, depending partly on and selection of participants.[51-73] Several of th…”
Result(2003) · Europe PMC (PubMed Central) · Cited by 176
Ondansetron: A Selective 5‐HT3Receptor Antagonist and Its Applications in CNS‐Related Disorders
Ye, J., Ponnudurai, R., & Schaefer, R. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00195.x · Cited by 162
Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
Baandrup, L., Ebdrup, B. H., Rasmussen, J. Ø., Lindschou, J., Gluud, C., & Glenthøj, B. Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011481.pub2 · Cited by 128
Metadata
- Authors
- Romach, M. K., Kaplan, H. L., Busto, U. E., Somer, G., & Sellers, E. M.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1998-04
- Volume
- 18
- Issue
- 2
- Pages
- 121-131
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2064874512
- Cited by
- 40
- References
- 8
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Controlled Trial of Ondansetron, a 5-HT3 Antagonist, in Benzodiazepine Discontinuation. https://app.cochat.ai/papers/10.1097/00004714-199804000-00004
- The paper
- Romach, M. K., Kaplan, H. L., Busto, U. E., Somer, G., & Sellers, E. M. (1998). A Controlled Trial of Ondansetron, a 5-HT3 Antagonist, in Benzodiazepine Discontinuation. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199804000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.